Several observational studies have compared the effectiveness and safety outcomes
between nonvitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists …

Background The non-vitamin K antagonist oral anticoagulants (NOACs) overcame some
limitations of vitamin K antagonists (VKAs), and are at least as effective in stroke prevention …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background This meta-analysis aimed to evaluate the efficacy and safety of non-vitamin K
antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in secondary …

Background and Purpose—To assess whether the combined analysis of all phase III trials of
nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and …

Introduction: Current evidence regarding the clinical outcomes of non-vitamin K oral
anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation (AF) and previous …

Background Patients with atrial fibrillation (AF) require oral anticoagulation to prevent
ischemic stroke. However, oral anticoagulation may cause bleeding, and patients with AF …

Findings of prior studies about the efficacy and safety of non‐vitamin K antagonist oral
anticoagulants (NOACs) in patients (≥ 80 years of age) with atrial fibrillation (AF) are …

Background In a previous systematic review and meta-analysis, we assessed the efficacy
and safety of nonvitamin-K antagonist oral anticoagulants versus warfarin in patients with …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …